截至发稿，荣昌生物市值为500亿元。 每经AI快讯，荣昌生物（SH 688331，收盘价：88.66元）10月30日晚间发布公告称，公司第二届第二十 九次董事会会议于2025年10月30日在公司会议室以现场结合通讯方式召开。会议审议了《关于公司 <2025年第三季度报告>的议案》等文件。 2024年1至12月份，荣昌生物的营业收入构成为：医药制造业占比99.61%，其他业务占比0.39%。 每经头条（nbdtoutiao）——多地出现"负电价"，既然卖电"不挣钱"，为何电厂不愿停机？ （记者 贾运可） ...

截至发稿，博瑞医药市值为226亿元。 每经头条（nbdtoutiao）——多地出现"负电价"，既然卖电"不挣钱"，为何电厂不愿停机？ （记者 王晓波） 每经AI快讯，博瑞医药（SH 688166，收盘价：53.44元）10月30日晚间发布公告称，2025年10月30日， 公司通过上海证券交易所交易系统以集中竞价交易方式首次回购公司股份约5.59万股，占公司总股本约 4.23亿股的比例为0.0132%，回购成交的最高价为54.28元/股、最低价为52.96元/股，支付的资金总额为 人民币约299万元。 2024年1至12月份，博瑞医药的营业收入构成为：医药制造业占比97.33%，其他业务占比2.67%。 ...

每经AI快讯，赛升药业（SZ 300485，收盘价：11.67元）10月30日晚间发布公告称，北京赛升药业股份 有限公司于2025年10月30日召开的第五届董事会第十一次会议审议通过了《关于公司拟出售部分交易性 金融资产的议案》，同意公司根据证券市场情况择机出售持有的北京绿竹生物技术股份有限公司及北京 康乐卫士生物技术股份有限公司股票。公司目前持有绿竹生物股票约1375万股，占其总股本的比例为 6.79%；持有康乐卫士股票约136万股，占其总股本的比例为0.4855%。 截至发稿，赛升药业市值为56亿元。 每经头条（nbdtoutiao）——多地出现"负电价"，既然卖电"不挣钱"，为何电厂不愿停机？ （记者 曾健辉） 2024年1至12月份，赛升药业的营业收入构成为：医药制造业占比99.63%，其他业务占比0.37%。 ...

证券代码：600682 证券简称：南京新百 公告编号：临 2025-031 南京新街口百货商店股份有限公司 2025年第三季度经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并 对其内容的真实性、准确性和完整性承担法律责任。 南京新街口百货商店股份有限公司（以下简称公司）根据上海证券交易所《上市 公司自律监管指引第 3 号——行业信息披露》之《第四号——零售》和《关于做好主 板上市公司 2025 年第三季度报告披露工作的重要提醒》的相关要求，现将公司 2025 年第三季度主要经营数据（未经审计）公告如下： 一、2025 年第三季度主要经营数据如下： （一）主营业务分行业情况 单位:元 币种:人民币 | 主营分行业 | 主营业务收入 | 主营业务成本 | 毛利率 | 营业收入比上 | 营业成本比上 | | --- | --- | --- | --- | --- | --- | | | | | （%） | 年增减（%） | 年增减（%） | | 商业 | 252,057,776.55 | 87,243,253.09 | 65.39 | -12.76 | -6.12 | ...

星标 ★ IPO日报 精彩文章第一时间推送 过去一周（10月20日-26日），证监会新增披露，湖北金龙新材料股份有限公司（下称"金龙新材"）、赛克赛斯生物科技股份有限公司（下称"赛克赛 斯"）、安徽国电电缆股份有限公司（下称"国电股份"）、欧尚元智能装备股份有限公司（下称"欧尚元"）、北京星河动力航天科技股份有限公司（下 称"星河动力"）、浙江邦盛科技股份有限公司（下称"邦盛科技"）、康佰家医药集团股份有限公司（下称"康佰家医药"）等7家公司进行了IPO辅导备案。 IPO日报注意到，金龙新材产品涉及军用帐篷及部队野营用品，隶属于湖北金龙集团公司；赛克赛斯曾两次谋求A股上市失败，更在现场检查中被存在多 项违规行为，被深交所书面警示；国电股份谋求北交所上市，出现增收不增利的情况；欧尚元作为有机酸生产核心设备供应商欲闯关创业板IPO；商业航 天领域星河动力创下国内民营火箭企业发射次数、服务客户数、发射卫星数、成功率四项第一，现开启上市之旅，最新投后估值超过150亿元；浙大教授 王新宇掌舵的邦盛科技闯关科创板失败后卷土重来；康佰家医药旗下坐拥2000多家门店，"大本营"在福建省现谋求上市。 张力制图 生产军用帐篷 金 ...

（记者 张明双） 每经AI快讯，康辰药业（SH 603590，收盘价：47.86元）10月29日晚间发布公告称，公司第四届第二十 一次董事会会议于2025年10月29日在北京市昌平区中关村生命科学园科学园路7号院3号楼公司第三会议 室以现场与通讯表决相结合的方式召开。会议审议了《关于2025年第三季度报告的议案》等文件。 2024年1至12月份，康辰药业的营业收入构成为：医药制造业占比99.88%，其他业务占比0.12%。 截至发稿，康辰药业市值为76亿元。 每经头条（nbdtoutiao）——"十五五"规划建议的18个新提法，释放了哪些重要信号？ ...

2025年以来，国内还有多只与自由现金流量指数挂钩的基金 产品获批发行。截至2025年9 月底，已有超过90支自由现金 流量ETF产品及其联接基金产品发行。因此，2025年堪称中 国资本市场基于自由现金流量创造理念开展投资的元年——自 由现金流量投资元年。 作者： 高若瀛 封图：图虫创意 《2024年度A股上市公司自由现金流量创造力99强（FCF Top 99）》榜单10月28日在京发布。与此同时，旨在揭示中国上市公司股东价值创造能力 的《A股上市公司现金增加值创造力50强（CVA Top 50）报告》《A股上市公司经济增加值创造力99强（EVA Top 99）报告》也同步发布。 这三大榜单报告，由清华大学经管学院教授、清华大学经济管理深圳研究院人工智能与资本市场研究中心副主任谢德仁带领团队连续第五年研究撰 写。 | 股票代码 | 公司简称 | FCFOE | 排名 | 股票代码 | 公司简称 | FCFOE | 排名 | 股票代码 | 公司简称 | FCFOE | 排名 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ...

Core Insights - The 2024 FCF Top 99 list was released on October 28, highlighting the free cash flow generation capabilities of A-share listed companies in China [1] - The report series, including CVA Top 50 and EVA Top 99, aims to reveal the shareholder value creation abilities of these companies [1] - The focus on free cash flow generation has led to the introduction of various index products linked to free cash flow by index companies [1] FCF Top 99 Summary - Guizhou Moutai (600519) and Focus Media (002027) share the highest net asset free cash flow return rate (FCFOE) at 0.361, up from 0.277 in 2023 [3] - Among the 16 companies listed continuously from 2016 to 2024, five are in the liquor sector, and two are in home appliances [3] - Gree Electric (000651) has seen a decline in ranking from a three-time champion to 8th place [3] Company Ownership Structure - The 2024 list includes 35 state-controlled companies, a decrease of 11 from the previous year, while non-state-controlled companies increased to 64, surpassing 60% [4] - The pharmaceutical manufacturing industry leads with 15 companies, followed by the beverage and refined tea manufacturing, and electrical machinery and equipment manufacturing with 12 each [4] CVA Top 50 Summary - The CVA Top 50 report indicates that only companies generating net profits or free cash flow exceeding the cost of equity capital create true shareholder value [5] - Among the 11 companies consistently listed from 2016 to 2024, five are in the liquor sector [5] - The number of state-controlled companies on the list decreased to 18, while non-state-controlled companies rose to 32, making up 64% [5] EVA Top 99 Summary - The EVA Top 99 list emphasizes that economic value added (EVA) reflects the true shareholder value creation by accounting for the cost of equity capital [6] - Chongqing Beer (600132) topped the list with an EVA return rate (EVAOE) of 0.297, while Guizhou Moutai ranked second at 0.235 [8] - The liquor industry dominates the top three positions in the EVA rankings [8] Long-term Trends - From 2016 to 2024, the liquor sector maintained a strong presence with six companies consistently listed, while the number of state-controlled companies decreased to 27 [9] - Non-state-controlled companies increased to 72, representing 72% of the total [9]

Core Insights - The profit of industrial enterprises above designated size in China increased by 3.2% year-on-year in the first nine months of the year, marking the highest cumulative growth rate since August of the previous year, with 26 industries showing improved profit growth or reduced declines [1][3] - In September alone, the profit growth rate surged to 21.6% year-on-year, an acceleration of 1.2 percentage points compared to August [2][3] Industry Performance - In September, 30 out of 41 major industrial sectors reported profit growth, with significant increases in sectors such as mining, pharmaceuticals, and chemical fiber manufacturing, where profits grew by over 100% month-on-month [5][6] - The mining sector's profit growth was primarily driven by a decrease in cost rates, which fell from 90.8% to 89%, leading to a profit margin increase from 1.1% to 2.3% [6][7] - The pharmaceutical manufacturing sector saw a profit increase due to a 31% year-on-year revenue growth and a seasonal decline in cost rates, with profit margins rising from 10% in August to 17% in September [6][7] - The chemical fiber manufacturing sector experienced a profit improvement despite a 2% decline in revenue, attributed to a rise in profit margins from 2.1% in August to 4.6% in September, supported by a 1.2 percentage point decrease in cost rates [7] Economic Factors - The significant profit increase in September is partly attributed to a low base effect from the previous year, where profits had decreased by 27.6% [3][4] - The overall profit growth is supported by a rebound in the Producer Price Index (PPI) and a continuous decline in expense ratios, which fell from 8.9% last year to 8.3% this year [3][4] - Future profit sustainability may depend on domestic demand expansion policies and external economic conditions, including U.S.-China negotiations and Federal Reserve interest rate paths [4]

Investment Rating - The investment rating for the company is "Outperform" (maintained) [1] Core Insights - The company's Q3 performance is generally in line with expectations, with a revenue of 293 million yuan for the first three quarters of 2025, representing a year-on-year increase of 15.7%, and a net profit attributable to shareholders of 48.06 million yuan, up 25.9% year-on-year [6] - The company is experiencing a trend of demand recovery, although domestic sales prices are under pressure due to centralized procurement [6] - The new factory's depreciation is impacting profitability, but the overall cost burden is gradually decreasing as the company completes provisions for financial product impairments [6] Financial Data and Profit Forecast - Total revenue for 2025 is projected to be 404 million yuan, with a year-on-year growth rate of 19.2% [5] - The net profit attributable to shareholders for 2025 is estimated at 63 million yuan, reflecting a year-on-year increase of 47.3% [5] - The company’s gross margin for Q3 2025 is reported at 31.8%, showing a year-on-year increase of 1.7 percentage points [6] - The company is expected to achieve revenues of 506 million yuan and 622 million yuan in 2026 and 2027, respectively [5]